Year 2024 / Volume 116 / Number 10
Editorial
Pancreatic cancer screening in high-risk individuals

519-522

DOI: 10.17235/reed.2024.10635/2024

Ana García García de Paredes, Emma Martínez Moneo, José Lariño-Noia, Julie Earl,

Abstract
The incidence of pancreatic cancer is increasing, although globally it represents less than 3% of all cancers. Despite advances in medical and surgical management, survival rates have not significantly improved in recent years. Consequently, pancreatic cancer, though relatively uncommon, is the third leading cause of cancer-related deaths. This is primarily due to the disease´s late detection. Symptoms appear late and are nonspecific, and over 80% of cases are diagnosed at an advanced stage and unsuitable for curative surgery, resulting in a five-year survival rate below 10%. However, the exceptional cases that are diagnosed early show five-year survival rates exceeding 80%. Therefore, one of the keys to improving pancreatic cancer prognosis lies in early detection, making screening in high-risk individuals a potentially crucial strategy.
Share Button
New comment
Comments
No comments for this article
References
1. Las cifras del Cancer en Espana 2024 [Internet]. [cited 2024 June 20]. Available from: https://www.seom.org/images/LAS_CIFRAS_2024.pdf
2. Cayuela L, Cayuela Dominguez A. Has the trend in pancreatic cancer mortality in Spain started to slow down? Rev Esp Enferm Dig. 2024;116(1):14-21. DOI: 10.17235/reed.2023.9573/2023
3. Carioli G, Malvezzi M, Bertuccio P, et al. European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer. Ann Oncol. 2021;32(4):478-87.
4. Blackford AL, Canto MI, Klein AP, et al. Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. J Natl Cancer Inst. 2020;112(11):1162-9.
5. Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7-17.
6. Force USPST, Owens DK, Davidson KW, et al. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2019;322(5):438-44.
7. Gardner TB, Adler DG, Forsmark CE, et al. ACG Clinical Guideline: Chronic Pancreatitis. Am J Gastroenterol. 2020;115(3):322-39.
8. Sharma A, Kandlakunta H, Nagpal SJS, et al. Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterology. 2018;155(3):730-9 e3.
9. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(4):439-57.
10. Carballal S, Balaguer F, Bujanda L, et al. Use of multi-gene panels in patients at high risk of hereditary digestive cancer: position statement of AEG, SEOM, AEGH and IMPaCT-GENOMICA consortium. Gastroenterol Hepatol. 2024;47(3):293-318.
11. Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review. Gastroenterology. 2020;159(1):358-62.
12. Sawhney MS, Calderwood AH, Thosani NC, et al. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc. 2022;95(5):817-26.
13. Ren B, Liu X, Suriawinata AA. Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: Histopathology, Cytopathology, and Molecular Pathology. Am J Pathol. 2019;189(1):9-21.
14. Overbeek KA, Koopmann BDM, Levink IJM, et al. Intraductal Papillary Mucinous Neoplasms in High-Risk Individuals: Incidence, Growth Rate, and Malignancy Risk. Clin Gastroenterol Hepatol. 2024;22(1):62-71 e7.
15. Sheel ARG, Harrison S, Sarantitis I, et al. Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer. Am J Gastroenterol. 2019;114(1):155-64.
16. Gonda TA, Farrell J, Wallace M, et al. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection Consortium. Gastrointest Endosc. 2022;95(4):723-32 e7.
17. Huang C, Simeone DM, Luk L, et al. Standardization of MRI Screening and Reporting in Individuals With Elevated Risk of Pancreatic Ductal Adenocarcinoma: Consensus Statement of the PRECEDE Consortium. AJR Am J Roentgenol. 2022;219(6):903-14.
18. Kogekar N, Diaz KE, Weinberg AD, Lucas AL. Surveillance of high-risk individuals for pancreatic cancer with EUS and MRI: A meta-analysis. Pancreatology. 2020;20(8):1739-46.
19. Dbouk M, Katona BW, Brand RE, et al. The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. J Clin Oncol. 2022;40(28):3257-66.
20. Overbeek KA, Levink IJM, Koopmann BDM, et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2022;71(6):1152-60.
21. Paiella S, Capurso G, Carrara S, et al. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Am J Gastroenterol. 2024;119(4):739-47.
22. Klatte DCF, Boekestijn B, Onnekink AM, et al. Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis. Gastroenterology. 2023;164(7):1223-31 e4.
23. Chhoda A, Vodusek Z, Wattamwar K, et al. Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis. Gastroenterology. 2022;162(3):786-98.
24. Paiella S, Secchettin E, Lionetto G, et al. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery. Ann Surg. 2024;279(1):37-44.
25. Ibrahim IS, Vasen HFA, Wasser M, et al. Cost-effectiveness of pancreas surveillance: The CDKN2A-p16-Leiden cohort. United European Gastroenterol J. 2023;11(2):163-70.
Related articles

Editorial

Different trends in stomach and pancreatic cancer mortality rates

DOI: 10.17235/reed.2024.10504/2024

Citation tools
García García de Paredes A, Martínez Moneo E, Lariño-Noia J, Earl J. Pancreatic cancer screening in high-risk individuals. 10635/2024


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 569 visits.
This article has been downloaded 220 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 06/07/2024

Accepted: 17/07/2024

Online First: 01/08/2024

Published: 09/10/2024

Article Online First time: 26 days

Article editing time: 95 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology